Skip to main content
. 2022 Apr 20;13:868020. doi: 10.3389/fimmu.2022.868020

Table 4.

Proportions of participants reporting specific adverse events by intervention group.

Characteristics Regimen started
BAM/ETE CAS/IMD p-value* Total
N= 237 N= 196 N= 433
Adverse events, n(%) 0.064
 Mild 8 (3.4%) 15 (7.7%) 23 (5.3%)
 Moderate 0 (0.0%) 7 (3.6%) 7 (1.6%)
 Severe 1 (0.4%) 0 (0.0%) 1 (0.2%)
 Drug related 6 (2.5%) 19 (9.7%) 0.001 25 (5.8%)
Individual events, n(%)
 Arthomyalgia 1 (0.4%) 2 (1.0%) 0.455 3 (0.7%)
 Asthenia 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Chills 0 (0.0%) 3 (1.5%) 0.056 3 (0.7%)
 Diarrhea 1 (0.4%) 1 (0.5%) 0.893 2 (0.5%)
 Fever 4 (1.7%) 17 (8.7%) <.001 21 (4.8%)
 Nausea 0 (0.0%) 4 (2.0%) 0.027 4 (0.9%)
 Sight decrease 0 (0.0%) 1 (0.5%) 0.271 1 (0.2%)
 Headache 0 (0.0%) 1 (0.5%) 0.271 1 (0.2%)
 Dyspnea 1 (11.1%) 1 (4.5%) 0.506 2 (6.5%)
 Abdominal pain 1 (11.1%) 0 (0.0%) 0.118 1 (3.2%)
 Hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Paraesthesia 1 (0.4%) 0 (0.0%) 0.363 1 (0.2%)
 Itch 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Skin rash 0 (0.0%) 2 (1.0%) 0.119 2 (0.5%)
 Dizziness 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Vomit 0 (0.0%) 1 (0.5%) 0.271 1 (0.2%)

*Chi-square or Mann-Whitney test as appropriate.

BAM/ETE, bamlanivimab/etesevimab; CAS/IMD, casirivimab/imdevimab; IQR, interquartile range; BMI, body mass index; SpO2, peripheral oxygen saturation.